Reuters logo
BRIEF-Aptevo Therapeutics presents clinical data on safety and efficacy of Ixinity in children with Hemophilia B
April 10, 2017 / 1:24 PM / 7 months ago

BRIEF-Aptevo Therapeutics presents clinical data on safety and efficacy of Ixinity in children with Hemophilia B

April 10 (Reuters) - Aptevo Therapeutics Inc

* Aptevo Therapeutics presents new clinical data evaluating the safety and efficacy of Ixinity in children with Hemophilia B

* Aptevo Therapeutics Inc - data suggest that Ixinity appears to be safe and well tolerated in the subject population

* Aptevo Therapeutics Inc - new data is comparable to results from overall patient population studied in pivotal clinical trial of Ixinity

* Aptevo Therapeutics - Adverse events in study believed to be related to Ixinity were hyperhidrosis, fever in one patient, hyperhidrosis in another patient

* Aptevo Therapeutics - “Look forward to building on data set in a pediatric setting to support a label expansion for ixinity in patients under 12 years of age” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below